Le Lézard
Classified in: Health, Science and technology
Subject: Contract/Agreement

Naveris Announces Commercial Payor Coverage for NavDx® Test from Highmark, Inc.

Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced that Highmark Inc. (Highmark), an independent licensee of the Blue Cross Blue Shield Association, now offers coverage for NavDx®, Naveris' proprietary flagship blood test for Tumor Tissue Modified Viral (TTMV®)-HPV DNA.

NavDx is the first and only clinically validated circulating TTMV-HPV DNA blood test. It provides a non-invasive and precise method for identifying HPV-driven cancers before there is clinical or radiographical evidence of disease. Data supporting the clinical validity and utility of NavDx have been published in nearly 20 peer-reviewed publications, and the test recently received Medicare coverage through the Molecular Diagnostics Services Program MolDX®.

"We are pleased that Highmark has made NavDx available to the patients who need the valuable insights provided by TTMV-HPV DNA," said James McNally, Chief Executive Officer of Naveris. "This test helps to optimize the management of HPV-driven cancer from diagnosis to post-treatment monitoring to surveilling for molecular residual disease. Receiving coverage from a payor that serves millions of patients is a meaningful step forward as we work to further expand access to NavDx."

About Naveris

Naveris is a privately held, commercial stage, precision oncology diagnostics company with facilities in Massachusetts and North Carolina. Since its founding in 2017, Naveris has been committed to improving outcomes for the millions of people at risk of developing viral-induced cancers with novel molecular diagnostics that enable earlier cancer detection. The company operates high-complexity testing clinical laboratories that are accredited by the College of American Pathologists and the New York State Department of Health Wadsworth Center, and are certified under CLIA. For more information on Naveris and the clinical impact of NavDx, please visit www.naveris.com and www.NavDx.com. NavDx has not been cleared or approved by the US Food and Drug Administration (FDA).

These press releases may also interest you

at 10:05
Guardian Pharmacy Services, celebrating 20 years as one of the nation's largest and most innovative long-term care (LTC) pharmacy companies, today announced a major seven state expansion in the western U.S. through a partnership with Heartland...

at 10:01
Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides data driven research and consulting support released highly valued Market Outlook Report Title: Asthma - Market...

at 10:00
Seniors Helping Seniors® in-home care services, a franchisor with over 125 franchise partners and more than 200 territories nationwide, has grown rapidly in recent years by building a workforce of talented caregivers who create meaningful...

at 10:00
Medicus IT, a leading provider of healthcare technology solutions and managed services on a national scale, proudly announces the acquisition of BlueNovo, a premier provider of physician and patient-centered healthcare, quality, and technology...

at 10:00
American Life League's newly named national director, Katie Brown, is a natural in her new role. Having been raised in the fight for life, Brown marks the third generation of her family to lead the 45-year-old pro-life organization and carries a full...

at 10:00
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented the preclinical research findings of three potential novel drug candidates in poster format at the American Association for Cancer Research...

News published on and distributed by: